New registry aims to improve detection of rare tumors
NCT ID NCT02270567
First seen Nov 15, 2025 · Last updated May 22, 2026 · Updated 24 times
Summary
This study is a registry for people with neuroendocrine tumors (NETs), a rare type of cancer. Researchers will collect medical data and blood samples from 400 participants to study how well certain blood tests can detect tumor activity, recurrence, and treatment response. The goal is to improve diagnosis and monitoring without invasive procedures.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOID are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Wren Laboratories
Branford, Connecticut, 06405, United States
Conditions
Explore the condition pages connected to this study.